TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06013488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Character Strengths Based Coaching Support
Description: Residential (five day) workshop and remote (weekly) telephonic support for 8 to 10 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Supervision
Description: Weekly face-to-face supervision by supervisor in groups of \~20 (1 supervisor for \~20 health workers)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Supervision
Description: Weekly face-to-face supervision by supervisor in groups of \~20 (1 supervisor for \~20 health workers)
Study: NCT05469178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Bemcentinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Bemcentinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Bemcentinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Bemcentinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Bemcentinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
Study: NCT06511869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205
Description: AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
Study: NCT05624424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
Study: NCT05469178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.
Study: NCT05768269

Intervention type: OTHER
Intervention: No Intervention
Description: As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
Study: NCT04883346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.
Study: NCT05190549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAV regimen bridging to HSCT
Description: The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.
Study: NCT06375330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoliArt
Description: PoliArt injections
Study: NCT04529538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Oral Polio Vaccine Type 1 (nOPV1)
Description: Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Oral Polio Vaccine Type 1 (nOPV1)
Description: Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Oral Polio Vaccine Type 3 (nOPV3)
Description: Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
Study: NCT05616065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinding to academic performance of candidate
Description: Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Interview methodology
Description: Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
Study: NCT06030895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tablets
Description: Sorafenib Tablets (200 -400 mg) twice daily
Study: NCT05624424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Study: NCT05330780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Room
Description: 8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
Study: NCT05907694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure
Description: Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
Study: NCT06060353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation Focused Psychotherapy (RFP-C)
Description: Regulation-focused psychotherapy for children (RFP-C; Hoffman, Rice, \& Prout, 2016) is a manualized, psychodynamic play therapy. Through 20 sessions (16 with the child and four parent meetings), RFP-C allows the child to understand the ways distressing affects are avoided and to explore alternative ways of coping with unpleasant affect. The clinician works to increase the child's understanding that all behavior, especially oppositional and disruptive behavior, has meaning in the service of emotional and behavioral regulation. This work is also done with the parents to better support the child in achieving symptom reduction and increased emotion regulation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental Awareness and Child Social Skills Group
Description: Parental awareness and child social skills group is a manualized group psychotherapy that involves twelve parallel sessions conducted separately with parents and children. The parent group involves modules related to psycho-education, role-play and awareness building activities on child needs \& rights, child temperament, praise \& acceptance, child play, limit setting, anger management, transmission of parenting styles through genograms and family trees. With children, the groups involve psycho-education and play based activities to build awareness on children's rights, temperament, feelings, play \& relationship skills, empathy \& praise, anger management.
Study: NCT05068661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.1% Injectable Solution
Description: DPE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.1% Injectable Solution
Description: DPE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: CSE
Study: NCT05165654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical Stimulation
Description: Transcranial electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Electrical Stimulation
Description: Transcranial electrical stimulation
Study: NCT04529538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Oral Polio Vaccine Type 3 (nOPV3)
Description: Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)
Description: The Sabin mOPV1 control vaccine contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)
Description: The Sabin mOPV1 control vaccine contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
Study: NCT06074822

Intervention type: OTHER
Intervention: Residual neuromuscular biopsy
Description: recovery of residual neuromuscular biopsy (nerve ans muscle)
Study: NCT06560450

Intervention type: DEVICE
Group type: OTHER
Intervention: Stride One
Description: Stride One is a smart insole that provides real-time audio feedback (cues) to the patient when performing a certain exercise. The goal of Stride One is to allow patients to practice walking more intensively and with higher quality during rehabilitation.
Study: NCT04529538

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
Description: the Sabin mOPV3 control vaccine contains ≥ 10\^5.8 CCID50 per 0.1 mL (2 drops) dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
Description: the Sabin mOPV3 control vaccine contains ≥ 10\^5.8 CCID50 per 0.1 mL (2 drops) dose.
Study: NCT06528431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinical tapering strategy
Description: Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step Wedge trial
Description: Step Wedge trial : At baseline, all the patients will receive in this study the standard adalimumab dosing regimen. At subsequent time points (steps), patients will begin the intervention of interest, here the tapering adalimumab strategy. The time at which a patient begins the intervention will be randomized. We fixed the time steps duration to 3 months that corresponds the frequency of there commended follow-up of RA patients
Study: NCT05002478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: Turn patient in prone position after surfactant administration.
Study: NCT04001114

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Sampling Research Cigarettes
Description: Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Sampling Research Cigarettes
Description: Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.
Study: NCT05515874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Ferumoxytol contains iron and is used for the treatment of anemia, so it may affect any iron supplementation prescribed by a physician. Iron is metabolized in the liver, so impaired liver function could interfere with the metabolism of ferumoxytol.~Patients will receive up to a total maximum ferumoxytol dose of 4 mg/kg (71.6 µmol Fe/kg) of body weight, diluted in 200 mL of 0.9% normal saline, at a rate of 10 ml/minute for 20 minutes, The injection rate and maximum dosage are well within the safety thresholds regarding the FDA recommendation of ferumoxytol use.
Study: NCT06075004

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Local Anesthetic Infiltration
Description: Sixty milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg will be deposited by the orthopedic surgeon at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block
Description: From a total of forty-five milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg, 15mL will be deposited by the orthopedic surgeon at the posterior periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure with the remaining 30mL.~After wound closure, an ultrasound-guided pericapsular nerve group block will be performed by an anesthesiologist by injecting 10mL of 0.5% bupivacaine + 5ug/mL epinephrine in the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle.
Study: NCT02658292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftifine hydrochloride foam, 3%
Description: Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
Study: NCT06298370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block plus intrathecal bupivacaine
Description: Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal bupivacaine will be administered at the L3-L4 intervertebral level with 10-15 mg bupivacaine while the patient is in a sitting position.The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
Study: NCT06134609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual intercourse
Description: Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
Study: NCT05129891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide G
Description: Tablet given orally
Study: NCT06298370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal bupivacaine and morphine
Description: Patients will receive intrathecal bupivacaine and morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block plus intrathecal bupivacaine and morphine
Description: Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal drugs. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a S22 Gauche 80 mm block needle. Subarachnoid block will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
Study: NCT05129891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide H
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide I
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 B
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 C
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 D
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 E
Description: Tablet given orally
Study: NCT05874011

Intervention type: OTHER
Intervention: understanding of prosody
Description: The inverse correlation test consists of having the same word heard twice, and asking which of the two sounds the most like a question. The exercise will be repeated several times, for a task that will take a total of about thirty minutes

Intervention type: OTHER
Intervention: understanding of prosody
Description: The inverse correlation test consists of having the same word heard twice, and asking which of the two sounds the most like a question. The exercise will be repeated several times, for a task that will take a total of about thirty minutes
Study: NCT05992740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscope
Description: bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscope
Description: bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
Study: NCT04464005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 33% solution
Description: Topical pads with cold magnesium sulfate 33% solution will be given 5 times/day for 15 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cold water
Description: Topical pads with cold water will be given 5 times/day for 15 minutes
Study: NCT05450549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL919
Description: Single doses
Study: NCT05562635

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5% polymer gel with CBD application
Description: Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 10% polymer gel with CBD application
Description: Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Application of placebo without CBD